Published in Mol Cell Biol on March 01, 2006
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
A dimerization-dependent mechanism drives RAF catalytic activation. Nature (2009) 5.39
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol (2008) 3.30
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J (2012) 2.09
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol (2009) 1.81
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF. Proc Natl Acad Sci U S A (2010) 1.67
Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell (2013) 1.67
Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol (2011) 1.65
Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta (2007) 1.64
A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. Nat Struct Mol Biol (2009) 1.48
Systematic quantification of negative feedback mechanisms in the extracellular signal-regulated kinase (ERK) signaling network. J Biol Chem (2010) 1.45
Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling. Mol Cell (2013) 1.37
Constitutive activation of Raf-1 induces glioma formation in mice. Neoplasia (2008) 1.36
14-3-3 Proteins: diverse functions in cell proliferation and cancer progression. Semin Cell Dev Biol (2011) 1.31
Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell (2014) 1.30
Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med (2012) 1.27
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27
A novel role for copper in Ras/mitogen-activated protein kinase signaling. Mol Cell Biol (2012) 1.24
Cyclic AMP-mediated cyst expansion. Biochim Biophys Acta (2010) 1.21
Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. J Cell Biol (2008) 1.14
Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet (2009) 1.13
The secret life of kinases: functions beyond catalysis. Cell Commun Signal (2011) 1.13
Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat Chem Biol (2013) 1.10
CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol Cell (2008) 1.08
Profiling of experience-regulated proteins in the songbird auditory forebrain using quantitative proteomics. Eur J Neurosci (2008) 1.04
Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization. J Biol Chem (2009) 1.03
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep (2014) 1.01
CNK and HYP form a discrete dimer by their SAM domains to mediate RAF kinase signaling. Proc Natl Acad Sci U S A (2008) 0.99
Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem (2010) 0.98
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors. Br J Cancer (2014) 0.97
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol (2011) 0.97
Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase. J Biol Chem (2011) 0.97
Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation. Mol Cell Biol (2010) 0.96
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J (2006) 0.93
Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci U S A (2013) 0.93
Dimerization in protein kinase signaling. J Biol (2006) 0.93
Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants. EMBO J (2015) 0.92
Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci Rep (2015) 0.92
C-RAF mutations confer resistance to RAF inhibitors. Cancer Res (2013) 0.91
"RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway. FEBS Lett (2014) 0.91
RASSF1A: Not a prototypical Ras effector. Small GTPases (2011) 0.90
Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol (2006) 0.89
The importance of Raf dimerization in cell signaling. Small GTPases (2013) 0.88
Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum. PLoS One (2013) 0.88
Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol (2012) 0.87
A bipolar clamp mechanism for activation of Jak-family protein tyrosine kinases. PLoS Comput Biol (2009) 0.87
IκB kinase-induced interaction of TPL-2 kinase with 14-3-3 is essential for Toll-like receptor activation of ERK-1 and -2 MAP kinases. Proc Natl Acad Sci U S A (2014) 0.85
Human cerebrovascular contractile receptors are upregulated via a B-Raf/MEK/ERK-sensitive signaling pathway. BMC Neurosci (2011) 0.85
Calcineurin increases glucose activation of ERK1/2 by reversing negative feedback. Proc Natl Acad Sci U S A (2010) 0.84
Hierarchical scaffolding of an ERK1/2 activation pathway. Cell Commun Signal (2013) 0.84
Catalytic mechanisms and regulation of protein kinases. Methods Enzymol (2014) 0.83
Raf kinase inhibitory protein (RKIP) as a metastasis suppressor: regulation of signaling networks in cancer. Crit Rev Oncog (2014) 0.83
Topological analysis of MAPK cascade for kinetic ErbB signaling. PLoS One (2008) 0.82
BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling. J Biol Chem (2011) 0.82
Negative feedback regulation of the ERK1/2 MAPK pathway. Cell Mol Life Sci (2016) 0.81
Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth. J Biol Chem (2014) 0.81
IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds. J Biol Chem (2008) 0.81
Mechanisms of GnRH-induced extracellular signal-regulated kinase nuclear localization. PLoS One (2012) 0.81
Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. Oncotarget (2015) 0.80
Human 14-3-3 gamma protein results in abnormal cell proliferation in the developing eye of Drosophila melanogaster. Cell Div (2008) 0.80
Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling. Proc Natl Acad Sci U S A (2017) 0.79
Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells. Am J Pathol (2015) 0.79
MEK-1 activates C-Raf through a Ras-independent mechanism. Biochim Biophys Acta (2013) 0.79
RKIP regulates MAP kinase signaling in cells with defective B-Raf activity. Cell Signal (2013) 0.79
Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. Small GTPases (2011) 0.79
H-ras Inhibits the Hippo Pathway by Promoting Mst1/Mst2 Heterodimerization. Curr Biol (2016) 0.79
Reactive oxygen species and epidermal growth factor are antagonistic cues controlling SHP-2 dimerization. Mol Cell Biol (2012) 0.78
Opioid receptor trafficking and signaling: what happens after opioid receptor activation? Cell Mol Neurobiol (2011) 0.77
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett (2016) 0.77
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol (2016) 0.77
Phosphorylation of RAF Kinase Dimers Drives Conformational Changes that Facilitate Transactivation. Angew Chem Int Ed Engl (2015) 0.77
Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors. Sci Rep (2016) 0.77
Contextual signaling in cancer. Semin Cell Dev Biol (2016) 0.76
Integrated modulation of phorbol ester-induced Raf activation in EL4 lymphoma cells. Cell Signal (2009) 0.76
Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma. Mol Carcinog (2015) 0.75
Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation. J Biol Chem (2016) 0.75
SPRED1 Interferes with K-ras but Not H-ras Membrane Anchorage and Signaling. Mol Cell Biol (2016) 0.75
The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF. J Biol Chem (2012) 0.75
Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF(V600E) Conformation. ACS Chem Biol (2016) 0.75
Dimerization-based control of cooperativity. Mol Biosyst (2014) 0.75
Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Oncotarget (2016) 0.75
Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition. EMBO J (2017) 0.75
ERK1/2 can feedback-regulate cellular MEK1/2 levels. Cell Signal (2015) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell (1993) 16.91
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
The RAF proteins take centre stage. Nat Rev Mol Cell Biol (2004) 8.04
Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. Anal Biochem (1994) 7.30
Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol (2005) 7.07
Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res (2001) 4.20
Signaling pathways for PC12 cell differentiation: making the right connections. Science (2002) 3.80
A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature (1998) 2.89
Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol (1995) 2.82
Endothelial apoptosis in Braf-deficient mice. Nat Genet (1997) 2.77
Identification of the major phosphorylation sites of the Raf-1 kinase. J Biol Chem (1993) 2.70
Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science (2004) 2.66
Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta (2003) 2.58
Mechanisms of regulating the Raf kinase family. Cell Signal (2003) 2.58
Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem (1997) 2.47
Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem (2001) 2.44
MEK kinase activity is not necessary for Raf-1 function. EMBO J (2001) 2.36
Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J (2001) 2.32
Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol Cell Biol (2000) 2.27
The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. J Biol Chem (1994) 2.16
Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J (2002) 1.99
Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem (2000) 1.87
Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J (2001) 1.81
Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest (2004) 1.79
Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biological signaling. Mol Cell Biol (1997) 1.79
14-3-3 Proteins--a focus on cancer and human disease. J Mol Cell Cardiol (2004) 1.67
Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem Biophys Res Commun (1997) 1.64
Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys (2002) 1.57
Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues. Mol Cell Biol (1994) 1.56
Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci (2002) 1.53
Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol (1996) 1.52
Formation of the Ras dimer is essential for Raf-1 activation. J Biol Chem (2000) 1.50
Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer (2004) 1.47
Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol (1996) 1.47
An intact Raf zinc finger is required for optimal binding to processed Ras and for ras-dependent Raf activation in situ. Mol Cell Biol (1997) 1.37
Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene (2003) 1.37
Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation. J Biol Chem (2004) 1.31
A-Raf and Raf-1 work together to influence transient ERK phosphorylation and Gl/S cell cycle progression. Oncogene (2005) 0.97
Involvement of B-Raf in Ras-induced Raf-1 activation. FEBS Lett (2001) 0.91
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet (2005) 3.49
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell (2007) 3.47
Signalling ballet in space and time. Nat Rev Mol Cell Biol (2010) 3.32
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science (2004) 2.66
The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier. Sci Signal (2010) 2.40
Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J (2002) 1.99
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res (2005) 1.78
Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition. Cancer Res (2010) 1.74
Raf family kinases: old dogs have learned new tricks. Genes Cancer (2011) 1.72
Computational modelling of the receptor-tyrosine-kinase-activated MAPK pathway. Biochem J (2005) 1.70
Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. J Clin Oncol (2006) 1.67
Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. Mol Cell Biol (2002) 1.63
Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res (2004) 1.61
Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip (2009) 1.61
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Untying the regulation of the Raf-1 kinase. Arch Biochem Biophys (2002) 1.57
Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal (2010) 1.54
Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J Cell Sci (2002) 1.53
Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models. Bioinformatics (2008) 1.51
Computational approaches for analyzing information flow in biological networks. Sci Signal (2012) 1.49
Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics (2007) 1.47
Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell (2011) 1.44
Oncogenic K-RAS is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. Cancer Res (2005) 1.41
Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway. J Cell Sci (2009) 1.41
Systems biology-embedded target validation: improving efficacy in drug discovery. Wiley Interdiscip Rev Syst Biol Med (2013) 1.41
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev (2004) 1.39
Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5. Nat Cell Biol (2006) 1.36
When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal (2013) 1.36
The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis (2002) 1.32
Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions. Mol Syst Biol (2009) 1.31
Modeling and simulation of intracellular dynamics: choosing an appropriate framework. IEEE Trans Nanobioscience (2004) 1.25
Emergence of bimodal cell population responses from the interplay between analog single-cell signaling and protein expression noise. BMC Syst Biol (2012) 1.25
Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal (2011) 1.21
MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol (2009) 1.20
Chip-based dynamic real-time quantification of drug-induced cytotoxicity in human tumor cells. Anal Chem (2009) 1.20
PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal (2010) 1.18
Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res (2010) 1.17
Raf kinase inhibitor protein RKIP enhances signaling by glycogen synthase kinase-3β. Cancer Res (2011) 1.17
Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics (2010) 1.16
Crosstalk and signaling switches in mitogen-activated protein kinase cascades. Front Physiol (2012) 1.16
Phosphatase and feedback regulation of Raf-1 signaling. Cell Cycle (2007) 1.15
ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol (2009) 1.14
The secret life of kinases: functions beyond catalysis. Cell Commun Signal (2011) 1.13
Discovery of biomarkers in human urine and cerebrospinal fluid by capillary electrophoresis coupled to mass spectrometry: towards new diagnostic and therapeutic approaches. Electrophoresis (2005) 1.12
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl (2010) 1.12
High-precision FLIM-FRET in fixed and living cells reveals heterogeneity in a simple CFP-YFP fusion protein. Biophys Chem (2007) 1.08
Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.06
RNA folding and catalysis mediated by iron (II). PLoS One (2012) 1.05
A Hippo in the ointment: MST signalling beyond the fly. Cell Cycle (2008) 1.03
A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation. Mol Cell Biol (2003) 1.03
Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle (2005) 1.02
ERK2 drives tumour cell migration in three-dimensional microenvironments by suppressing expression of Rab17 and liprin-β2. J Cell Sci (2012) 1.01
Switches, excitable responses and oscillations in the Ring1B/Bmi1 ubiquitination system. PLoS Comput Biol (2011) 1.00
Giving space to cell signaling. Cell (2008) 0.99
Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res (2010) 0.98
Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell (2004) 0.98
Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp Cell Res (2007) 0.97
Proteomic analysis of phosphorylation, oxidation and nitrosylation in signal transduction. Biochim Biophys Acta (2006) 0.97
RAF kinase inhibitory protein (RKIP) modulates cell cycle kinetics and motility. Mol Biosyst (2010) 0.96
Mammalian sterile 20-like kinases in tumor suppression: an emerging pathway. Cancer Res (2005) 0.96
Proteomics and phosphoproteomics for the mapping of cellular signalling networks. Proteomics (2008) 0.95
Use of the xCELLigence system for real-time analysis of changes in cellular motility and adhesion in physiological conditions. Methods Mol Biol (2013) 0.94
RAN GTPase is a RASSF1A effector involved in controlling microtubule organization. Curr Biol (2009) 0.94
LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol (2003) 0.94
Induction of apoptosis by protein kinase C delta is independent of its kinase activity. J Biol Chem (2002) 0.93
Phosphodiesterase-8A binds to and regulates Raf-1 kinase. Proc Natl Acad Sci U S A (2013) 0.93
c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway. Cancer Res (2011) 0.93
A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res (2012) 0.93
The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal (2009) 0.92
Extracellular signal-regulated kinase regulates RhoA activation and tumor cell plasticity by inhibiting guanine exchange factor H1 activity. Mol Cell Biol (2013) 0.92
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA (2014) 0.92
Cell type-specific activation of AKT and ERK signaling pathways by small negatively-charged magnetic nanoparticles. Sci Rep (2012) 0.91
Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal (2010) 0.91
Regulation of human myoblast differentiation by PEBP4. EMBO Rep (2009) 0.91
Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin Cancer Res (2013) 0.90
Identification of potential HLA class I and class II epitope precursors associated with heat shock protein 70 (HSPA). Cell Stress Chaperones (2010) 0.90
Pseudophosphatase STYX modulates cell-fate decisions and cell migration by spatiotemporal regulation of ERK1/2. Proc Natl Acad Sci U S A (2013) 0.89
The RKIP (Raf-1 Kinase Inhibitor Protein) conserved pocket binds to the phosphorylated N-region of Raf-1 and inhibits the Raf-1-mediated activated phosphorylation of MEK. Cell Signal (2008) 0.89
Investigating dynamics of inhibitory and feedback loops in ERK signalling using power-law models. Mol Biosyst (2010) 0.89
HGF induces epithelial-to-mesenchymal transition by modulating the mammalian hippo/MST2 and ISG15 pathways. J Proteome Res (2014) 0.89
Engineering the serine/threonine protein kinase Raf-1 to utilise an orthogonal analogue of ATP substituted at the N6 position. FEBS Lett (2004) 0.88
Multiple roles of the NF-kappaB signaling pathway regulated by coupled negative feedback circuits. FASEB J (2009) 0.88
Raf kinase inhibitor protein expression combined with peritoneal involvement and lymphovascular invasion predicts prognosis in Dukes' B colorectal cancer patients. Histopathology (2013) 0.88
Menin determines K-RAS proliferative outputs in endocrine cells. J Clin Invest (2014) 0.88
It takes two to tango--signalling by dimeric Raf kinases. Mol Biosyst (2013) 0.88
Domain III of the T. thermophilus 23S rRNA folds independently to a near-native state. RNA (2012) 0.87
Raf kinase inhibitor protein regulation of raf and MAPK signaling. Methods Enzymol (2006) 0.87
Biology using engineering tools: the negative feedback amplifier. Cell Cycle (2011) 0.87
Big signals from small particles: regulation of cell signaling pathways by nanoparticles. Chem Rev (2013) 0.87